Prevalence and clinical characteristics of probable familial chylomicronaemia syndrome at a tertiary care center in Pakistan: Insights from a hospital-based screening study [0.03%]
巴基斯坦三级医疗中心疑似家族性乳糜微粒血症综合征的患病率和临床特征：来自医院筛查研究的见解
Quratul Ain,Naim-Ul Huda,Madeeha Khan et al.
Quratul Ain et al.
Background: Familial chylomicronaemia syndrome (FCS) is a rare monogenic disorder characterized by severe hypertriglyceridemia (HTG) and recurrent acute pancreatitis. Despite its significant morbidity, data from South Asi...
JCL Roundtable: Rewriting the rules for primary prevention: New outcomes from intensive LDL-C reduction in high-risk patients [0.03%]
JCL圆桌讨论：高危患者强化降低LDL-C治疗的新结局将重新定义一级预防规则
Robert P Giugliano,Nicholas A Marston,Kevin C Maki
Robert P Giugliano
This Journal of Clinical Lipidology Roundtable presents a conversation between Drs Robert P. Giugliano, Nicholas A. Marston, and Kevin C. Maki, who discussed clinical trials investigating intensive low-density lipoprotein cholesterol (LDL-C...
Efficacy and safety of inclisiran monotherapy in Chinese adults with elevated low-density lipoprotein cholesterol: Results from the VICTORION-Mono China trial [0.03%]
inclisiran单药治疗中国低密度脂胆固醇升高患者的疗效和安全性：VICTORION-MONO中国试验结果
Yong Huo,Janna Sand Dejmek,Zuyi Yuan et al.
Yong Huo et al.
Background: Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of death in China. Elevated low-density lipoprotein cholesterol (LDL-C) is a major, modifiable cardiovascular disease and mortality risk...
Apolipoprotein B-low-density lipoprotein cholesterol discordance refines cardiovascular risk stratification across metabolic phenotypes [0.03%]
载脂蛋白B与低密度脂胆固醇不一致可改善代谢分型患者的心血管风险分类
Jee Ah Kim,Min-Seung Park,Eun Hye Cho et al.
Jee Ah Kim et al.
Background: The cardiovascular risk of metabolically healthy obesity (MHO) remains controversial. Discordance between apolipoprotein B (apoB) and low-density lipoprotein cholesterol (LDL-C) reflects residual atherogenic r...
Does impaired HDL anti-inflammatory capacity reflect residual atherosclerotic risk or cardiorenal vulnerability? [0.03%]
HDL抗炎能力受损反映残余动脉粥样硬化风险还是 cardiorenal 脆弱性？
Zhaonan Li,Wenxiu Liu,Kang Yi et al.
Zhaonan Li et al.
Incidental steatotic liver in young patients with ischemic stroke: A marker of high vascular burden and underrecognized prevention opportunity [0.03%]
青年脑梗死患者中意外发现肝脂肪变性与高血管负担有关及被低估的预防机会的关系研究
Gourisree Dharmavaram,Sarina Chadha,Gavin McLaren et al.
Gourisree Dharmavaram et al.
Background: Ischemic stroke in adults younger than 60 years often occurs in the setting of underrecognized cardiometabolic risk. Objective and methods: ...
Impact of PREVENT-ASCVD vs pooled cohort equations on statin eligibility across demographic groups: Insights from the NIH All of Us Research Program [0.03%]
与PREVENT-ASCVD相比，使用汇集队列方程对不同的人群亚组他汀类药物适用性的影响：来自NIH全民研究计划的见解
Cammie Young,Frances Golden,Wenjun Fan et al.
Cammie Young et al.
We compared the predicting risk of cardiovascular EVENTS-atherosclerotic cardiovascular disease (PREVENT-ASCVD) risk equation with the pooled cohort equation (PCE) for estimating statin eligibility across demographic subgroups in the All of...
Utility of clinical scoring systems, laboratory, and genetic testing for appropriate classification of patients with severe hypertriglyceridemia in a Latin American cohort [0.03%]
临床评分系统、实验室和基因检测在拉美地区严重高甘油三酯血症患者分类中的应用价值评估研究
Gregorio Fariña,Amira Sleiman,Rodrigo Alonso et al.
Gregorio Fariña et al.
Background: Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia (sHTG) due to variants in canonical genes (LPL [lipoprotein lipase], APOA5, APOC2, GP...
Lipoprotein(a) and aortic diseases: Epidemiological evidence from observation to causation [0.03%]
脂蛋白(a)与主动脉疾病：从观察到因果关系的流行病学证据
Dexiang Xia,Lei Zhang,Junjie Fang et al.
Dexiang Xia et al.
Background: Aortic aneurysm and dissection (AA/AD) are life-threatening vascular diseases with high mortality, yet no effective drugs to delay progression. Lipoprotein(a) [Lp(a)] is genetically determined and associated w...
The 2026 Guideline on the Management of Dyslipidemia supports future quality measure compliance [0.03%]
2026年血脂管理指南助力未来达标质量测量指标要求达标率
Kaye-Eileen Willard,Brian Hart
Kaye-Eileen Willard